deCODE genetics, Inc. (deCODE) is a bio-pharmaceutical company developing and marketing products for the treatment, diagnosis, and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in therapeutic areas, and applies its discoveries in human genetics to bring to market deoxyribonucleic acid (DNA)-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. In November 2009, the Company announced that it has filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code with the United States Bankruptcy Court for the District of Delaware.

Naturewell, Incorporated does not have significant operations. Naturewell company intends to seek business opportunities, including an acquisition or merger with an operating business. Previously, it engaged in the research and development of proprietary healthcare products for various conditions, which comprise primary migraine medication, MIGRASPRAY. Naturewell company is based in San Diego, California.

New Leaf Brands, Inc. engages in the development, marketing, and distribution of ready-to-drink (RTD) beverages. Products The company’s New Leaf brand is a natural tea sweetened with organic cane sugar and specifically formulated to address the market for a healthy but appealing beverage. New Leaf is available in 13 flavors, integrating blue teas, green teas, black teas, and white teas. New Leaf products consist of Blue Teas, such as Diet Blue Tea with Lemon, Diet Blue Tea with Peach, Blue Tea with Lemon, Blue Tea with Peach, and Blue Tea with Raspberry; Green Teas, such as Green Tea with Plum, Green Tea with Ginseng, and Green Tea with Mango; White Teas, such as White Tea with Ginseng & Honey, White Tea with Honey Dew Melon, White Tea with Strawberry, and White Tea with Tangerine; and Black Tea: Mint & Lime International Sales The company sells its New Leaf brands in Canada and the Carribean. Customers New Leaf Tea is marketed to distributors, such as natural food, gourmet food, and mainstream distributors. The company’s major distributor is Manhattan Beer. Competition The company competes with soft drink companies, such as Coca Cola, Pepsi, and Cadbury Schweppes. In addition, it competes with beverage companies, including Arizona, Snapple, Lipton Brisk, Sobe, Vitamin Water, Fuze, Nestea, Tazo, Honest Tea, and Sweet Leaf Tea. Dispositions On October 9, 2009, the company completed the sale of its nutraceutical business, Nutritional Specialties, Inc. History The company was incorporated in 1986. It was formerly known as Baywood International, Inc. and changed its name to New Leaf Brands, Inc. on October 19, 2009.

EpiCept has made leukemia remission its entire mission. Its lead cancer drug candidate, Ceplene, is designed for use in adult patients who have had a complete remission from acute myeloid leukemia, but who are still at risk for relapse. It has been approved for use, along with interleukin-2, as a remission maintenance therapy in the EU, and it is awaiting approval in the US. The company's pipeline includes other cancer candidates, as well as topical analgesics for both acute and chronic pain. However, EpiCept has put all drug-discovery work on the back burner to focus on bringing Ceplene to market.

Ambrilia Biopharma likes to work with drug candidates when they're still in the early stages of development. Once they hit late stage, the company prefers to license them out for further development. The company is also working to manufacture better formulations of existing drugs to bring in cash. Ambrilia's pipeline includes anti-virals and a handful of oncology drug candidates including generic candidates Octreotide and Goserelin. While it is shifting its focus onto anti-viral drugs, the company is continuing with clinical trials of the two oncology drugs. Mid-shift, however, the company's funds dried up and it filed for bankruptcy protection in the Canadian courts.

Harlan was found in 1931 by Howard Harlan. Harlan Laboratories (formerly Harlan Sprague Dawley) is where scientists go when they need rats for the maze. Among other things, the research company produces laboratory animals and laboratory animal diets. The company is comprised of two operating groups. The Research Models group provides rodents and large animals, animal diets and bedding, and testing services to pharmaceutical and biotech companies, universities, and government agencies. The Contract Research Services division provides researchers with analytical chemistry services, toxicology services, and chemical and agrochemical registration.

The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey. The Medicines Company, a pharmaceutical company, provides medicines for the treatment of critical care patients worldwide. It markets Angiomax, an intravenous direct thrombin inhibitor for use as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty; and Cleviprex, a dihydropyridine calcium channel blocker, for the control of high blood pressure. The company's development products include cangrelor, an injectable antiplatelet agent that prevents platelet activation and aggregation in the clotting process; Oritavancin, a semi-synthetic lipoglycopeptide antibiotic for the treatment of gram-positive infections; and CU-2010 for the prevention of blood loss during surgery. Its customers include hospital management, physicians, hospital pharmacists, nurses, and other care staff. The Medicines Company sells its products through sales representatives and managers. The company has commercial supply agreement with Lonza Braine S.A. for the development and supply of the Angiomax bulk drug substance.

Centocor Ortho Biotech has ways of making your immune system behave itself. The Johnson & Johnson subsidiary makes blockbuster biotech drug Remicade, a monoclonal antibody used to treat a number of autoimmune conditions, or diseases in which the body's immune system attacks its own tissues. It is approved in the US and Europe for several indications, including Crohn's disease, ulcerative colitis, psoriasis, rheumatoid arthritis, and ankylosing spondylitis (a type of arthritis of the spine). The company also makes oncology drugs Doxil and Leustatin, and immunosuppressant Orthoclone for organ transplantation.

Impax Laboratories, Inc. company was founded in 1993 and is headquartered in Hayward, California. mpax Laboratories, Inc. engages in the development and commercialization of bioequivalent and brand-name pharmaceuticals. It operates through two divisions, Global Pharmaceuticals and Impax Pharmaceutical. The Global Pharmaceuticals division develops, formulates, manufactures, and sells controlled release and specialty generic pharmaceutical products. This division offers generic prescription products directly to wholesalers and large retail drug chains; and generic over-the-counter and generic prescription products through unrelated third-party pharmaceutical entities. The Impax Pharmaceutical division develops proprietary brand pharmaceutical products that address central nervous system disorders, including Alzheimer's disease, attention deficit hyperactivity disorder, depression, epilepsy, migraines, multiple sclerosis, Parkinson's disease, and schizophrenia. As of March 10, 2009, the company marketed 70 generic pharmaceuticals representing dosage variations of 24 different pharmaceutical compounds through its Global Pharmaceuticals division, as well as 16 products representing dosage variations of 4 different pharmaceutical compounds through its alliance agreements partners. Impax Laboratories markets and sells its generic pharmaceutical prescription drug products in the continental United States of America and the Commonwealth of Puerto Rico. It has alliance agreements with Teva Pharmaceutical Industries, Ltd.; Wyeth; Schering-Plough Corporation; and DAVA Pharmaceuticals, Inc.

New Brunswick Scientific Co. was founded in 1946 and is headquartered in Edison, New Jersey. As of September 24, 2007, New Brunswick Scientific Co. Inc. is a subsidiary of Eppendorf AG. New Brunswick Scientific Co., Inc. and its subsidiaries provide various research equipment and scientific instruments for the life sciences industry. It engages in the design, manufacture, and marketing of equipment that creates, maintains, measures, and controls the physical and biochemical conditions required for the growth, detection, and storage of biological cultures. The company’s products include fermentation equipment, bioreactors, biological shakers, ultra-low temperature freezers, CO2 incubators, nutrient sterilizing and dispensing equipment, tissue culture apparatus, and air samplers. Its products are used in medical, biological, chemical, and environmental research; and for the commercial development of antibiotics, proteins, hormones, enzymes, monoclonal antibodies, agricultural products, fuels, vitamins, vaccines, and other substances. The company sells its equipment to biotechnology and pharmaceutical companies; agricultural and chemical companies; other industrial customers engaged in biotechnology; and medical schools, universities, research institutes, hospitals, and private laboratories; and laboratories of federal, state, and municipal government departments and agencies. It also sells its equipment directly, as well as through scientific equipment dealers to foreign companies, institutions, and governments. The company primarily operates in the United States, Asia, and Europe.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.